Histopathological investigation of 1p/19q-codeled gliomas resected following alkylating agent chemotherapy

2020 Fiscal Year Final Research Report

• Project/Area Number: 19K18441
• Research Category: Grant-in-Aid for Early-Career Scientists
• Allocation Type: Multi-year Fund
• Review Section: Basic Section 56010:Neurosurgery-related
• Research Institution: Keio University
• Principal Investigator: ICHIMURA Saeko 慶應義塾大学, 医学部(信濃町), 共同研究員 (30464952)
• Project Period (FY): 2019-04-01 – 2021-03-31
• Keywords: 神経膠腫 / 1p/19q / 化学療法 / 抵抗性 / neoadjuvant chemotherapy / 組織

Outline of Final Research Achievements

1p/19q-codeleted gliomas are often responsive to alkylating agent chemotherapy, and we have been treating patients with those tumors with upfront chemotherapy and subsequent resection strategy. We investigated tumor specimens of 1p/19q-codeleted diffuse gliomas resected following tumor volume decrease after alkylating agent chemotherapy in 15 cases and compared them with their pre-chemotherapy specimens. In the post-chemotherapy specimens, the MIB-1 proliferative index decreased, the ratio of glioma-stem cells increased, and the number of tumor infiltrative macrophage increased post-chemotherapy, and the relevance of these findings to patient prognois was also investigated. These findings would help to clarify the mechanism of resistance to and recurrence after chemotherapy in 1p/19q-codeleted gliomas, and to establish new therapies with the aim of cure of the disease.

Free Research Field

脳腫瘍

Academic Significance and Societal Importance of the Research Achievements

WHO grade 2, 3神経膠腫は、IDH変異と1p/19q共欠失の有無により３群に分類される。その中で、1p/19q共欠失を持つ神経膠腫は、比較的化学療法反応性が高いことが知られているが、必ず再発し、未だに多くの患者は原病死を免れない。今回の知見は、神経膠腫の化学療法抵抗性及びその後の再発メカニズムの解明、さらには、効果的な治療法開発に有用と考えられた。